Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Kuros Biosciences AG
  6. Summary
    KURN   CH0325814116

KUROS BIOSCIENCES AG

(KURN)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
2.56(c) 2.57(c) 2.5(c) 2.57(c) 2.55 Last
47 063 17 160 36 902 5 049 1 535 Volume
+0.39% +0.39% -2.72% +2.80% -0.78% Change
More quotes
Estimated financial data (e)
Sales 2019 2,56 M 2,83 M 2,83 M
Net income 2019 -11,3 M -12,4 M -12,4 M
Net cash position 2019 18,4 M 20,3 M 20,3 M
P/E ratio 2019 -3,45x
Yield 2019 -
Sales 2020 4,04 M 4,46 M 4,46 M
Net income 2020 -11,5 M -12,7 M -12,7 M
Net cash position 2020 26,0 M 28,7 M 28,7 M
P/E ratio 2020 -4,26x
Yield 2020 -
Capitalization 84,3 M 93,1 M 93,0 M
EV / Sales 2019 14,3x
EV / Sales 2020 9,97x
Nbr of Employees 46
Free-Float 74,3%
More Financials
Company
Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct... 
More about the company
All news about KUROS BIOSCIENCES AG
07/16XOMA Acquires Royalty and Milestone Interest in Checkmate's Vidutolimod (CMP-..
AQ
07/15XOMA : Acquires Royalty Interest in Checkmate's Vidutolimod From Kuros Bioscienc..
MT
07/15Kuros to receive $7 million up front and potentially $166.5 million in future..
GL
07/15KUROS BIOSCIENCES : Enters Royalty Purchase Deal With US-Based Xoma
MT
07/15KUROS BIOSCIENCES : to receive $7 million up front and potentially $166.5 millio..
EQ
07/15EQS-ADHOC : Kuros to receive USD7 million up front and potentially USD166.5 mill..
DJ
07/15Kuros Biosciences AG Enters into a Royalty Purchase Agreement with Xoma Corpo..
CI
06/22KUROS BIOSCIENCES : Says MagnetOs Leads to Enhanced Bone Regeneration
MT
06/22KUROS BIOSCIENCES : Press Release, 22 June 2021
PU
06/22EQS-ADHOC : Kuros Biosciences announces publication of data on MagnetOs in eCM J..
DJ
06/22Kuros Biosciences Announces Publication of Data on Magnetos in eCM Journal Li..
CI
06/17KUROS BIOSCIENCES : Press Release, 17 June 2021
PU
06/17KUROS BIOSCIENCES : to present at upcoming U.S. spine conferences
EQ
06/02KUROS BIOSCIENCES : Q1 MagnetOs US Sales Soar 117%
MT
06/02KUROS BIOSCIENCES : Press Release, 2 June 2021
PU
More news
News in other languages on KUROS BIOSCIENCES AG
07/15Kuros signe un accord de licence avec l'américain Xoma
07/15Kuros fliesst wegen Lizenzabkommen mit XOMA erste Zahlung über 7 Mio USD zu
06/22Kuros veröffentlicht neue Daten zu Knochentransplantat MagnetOs in Fachjourna..
06/17Kuros wird an zahlreichen Fachkonferenzen Studiendaten präsentieren
06/02KUROS : ventes et distribution de MagnetOs supérieures aux attentes
More news
Analyst Recommendations on KUROS BIOSCIENCES AG
More recommendations
Chart KUROS BIOSCIENCES AG
Duration : Period :
Kuros Biosciences AG Technical Analysis Chart | KURN | CH0325814116 | MarketScreener
Technical analysis trends KUROS BIOSCIENCES AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Joost D. de Bruijn Chief Executive Officer & Director
Michael Grau Chief Financial Officer
Clemens A. van Blitterswijk Chairman
Pascal Longlade Chief Medical Officer
Jason M. Hannon Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
KUROS BIOSCIENCES AG27.23%93
GILEAD SCIENCES, INC.20.25%87 579
BIONTECH SE283.45%75 497
WUXI APPTEC CO., LTD.38.94%70 844
REGENERON PHARMACEUTICALS21.38%60 387
VERTEX PHARMACEUTICALS-15.22%51 872